AU2001224718A1 - A medicinal aerosol formulation - Google Patents

A medicinal aerosol formulation

Info

Publication number
AU2001224718A1
AU2001224718A1 AU2001224718A AU2471801A AU2001224718A1 AU 2001224718 A1 AU2001224718 A1 AU 2001224718A1 AU 2001224718 A AU2001224718 A AU 2001224718A AU 2471801 A AU2471801 A AU 2471801A AU 2001224718 A1 AU2001224718 A1 AU 2001224718A1
Authority
AU
Australia
Prior art keywords
aerosol formulation
medicinal aerosol
medicinal
formulation
aerosol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001224718A
Inventor
Akwete L. Adjei
Anthony J. Cutie
Frederick A. Sexton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aeropharm Technology LLC
Original Assignee
Aeropharm Technology LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aeropharm Technology LLC filed Critical Aeropharm Technology LLC
Publication of AU2001224718A1 publication Critical patent/AU2001224718A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2001224718A 2000-05-01 2001-01-02 A medicinal aerosol formulation Abandoned AU2001224718A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20122900P 2000-05-01 2000-05-01
US60201229 2000-05-01
US09/702,201 US6548049B1 (en) 2000-05-01 2000-10-31 Medicinal aerosol formulation
US09702201 2000-10-31
PCT/US2001/000035 WO2001082874A2 (en) 2000-05-01 2001-01-02 A medicinal aerosol formulation

Publications (1)

Publication Number Publication Date
AU2001224718A1 true AU2001224718A1 (en) 2001-11-12

Family

ID=26896531

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001224718A Abandoned AU2001224718A1 (en) 2000-05-01 2001-01-02 A medicinal aerosol formulation

Country Status (3)

Country Link
US (1) US6548049B1 (en)
AU (1) AU2001224718A1 (en)
WO (1) WO2001082874A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7074388B2 (en) * 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
EP1465622A1 (en) * 2001-11-26 2004-10-13 Arachnova Therapeutics Ltd. Use of ppar activators for the treatment of pulmonary fibrosis
JP2005527537A (en) * 2002-03-21 2005-09-15 テバ ファーマシューティカル インダストリーズ リミティド Fine particle size pioglitazone
AU2003303634B2 (en) 2002-12-27 2009-10-01 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US7299802B2 (en) * 2003-06-17 2007-11-27 Spencer Feldman Carbon dioxide delivery apparatus and method for using same
US7824436B2 (en) * 2005-05-13 2010-11-02 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
US9358150B2 (en) 2005-05-13 2016-06-07 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling alternating liquid mist/gas for induction and gas for maintenance
US8721699B2 (en) * 2005-05-13 2014-05-13 Benechill, Inc. Methods and devices for non-invasive cerebral and systemic cooling
US20100174278A1 (en) * 2008-11-07 2010-07-08 Denise Barbut Methods of nasopharyngeal cooling for augmenting coronary perfusion pressure
WO2010148372A1 (en) 2009-06-19 2010-12-23 Benechill Devices for cooling the nasal cavity
TWI399202B (en) 2011-03-17 2013-06-21 Intech Biopharm Ltd The preparation for formulation composition and manufacturing processes of metered dose inhalers treated respiratory diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011678A (en) 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
WO1990009781A1 (en) 1989-02-23 1990-09-07 Rorer International (Holdings), Inc. Therapeutic aerosol formulations
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
AU679511B2 (en) * 1993-03-17 1997-07-03 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
SK81197A3 (en) 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US6193954B1 (en) 1997-03-21 2001-02-27 Abbott Laboratories Formulations for pulmonary delivery of dopamine agonists

Also Published As

Publication number Publication date
WO2001082874A2 (en) 2001-11-08
WO2001082874A3 (en) 2002-04-25
US6548049B1 (en) 2003-04-15

Similar Documents

Publication Publication Date Title
AU2001224716A1 (en) A medicinal aerosol formulation
AU2001226233A1 (en) A medicinal aerosol formulation
EP1296723A4 (en) A medicinal aerosol formulation
AU2753001A (en) A medicinal aerosol formulation
AU4519001A (en) A medicinal aerosol formulation
AU2002218250A1 (en) Medicament dispenser
AU6310000A (en) Aerosol formulations
IL155088A0 (en) Medicinal aerosol formulations
AU2002223562A1 (en) Medicament dispenser
AUPR054400A0 (en) A castor
AU2001227535A1 (en) A core formulation
AU2001227532A1 (en) A core formulation
AU2001224718A1 (en) A medicinal aerosol formulation
AU2623401A (en) A medicinal aerosol formulation
AUPR000900A0 (en) A berley dispenser
AU2001259318A1 (en) A medicinal aerosol formulation
AU1141101A (en) Pharmaceutical aerosol formulations comprising s-salmeterol
HUP0600143A2 (en) A stable pharmaceutical formulation comprising torsemide modification ii
AU2001247123A1 (en) A medicinal aerosol formulation
AU2001227531A1 (en) A medicinal aerosol formulation
EP1292283A4 (en) A medicinal aerosol formulation
AU2001267135A1 (en) Medicaments
AU2002215902A1 (en) Medicament dispenser
GB0014849D0 (en) Pharmaceutical aerosol formulation
AU2002223437A1 (en) Medicament dispenser